[PonkenPlonken]

they all leave and the stock keeps declining...
Imagine FOUSE leaving.... stock would be up?

[PonkenPlonken]

aged well
FOUSE and Schenkein too busy delaying trials and engagin the analyst to pump their stock.

[PonkenPlonken]

management selling a sheet ton of shares vs delivering and helping patients.
its still a good product

[Monksdream]

AGIO new 52 week high

[Monksdream]

AGIO new 52 week high

[TonyJoe1957]

Do you have any estimates?

[TonyJoe1957]

Lots of posts.
There is a short position that will have to be covered, so a short squeeze is probably in progress.
Stay safe.

[whytestocks]

News: $AGIO Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors

There's an old adage in biotech -- raise capital when you can, not when you have to -- that  Agios Pharmaceuticals (NASDAQ: AGIO) seems to have taken to heart. The biotech ended the third quarter with over $540 million in the bank, which it estimated would last through at least the end o...

Got this from AGIO - Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors

[whytestocks]

News: $AGIO Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

– Plasma SAM Biomarker Indicates Robust Target Engagement at Well Tolerated Doses; AG-270 Maximum Tolerated Dose Determined to be 200 mg Once Daily – – Combination Arms of Phase 1 Study Evaluating AG-270 in Combination with Taxanes in Non-Small Cell Lung Cancer an...

In case you are interested AGIO - Agios Presents Data from Single Agent Dose-Escalation Arm of Phase 1 Study of AG-270, a MAT2A Inhibitor, in Patients with MTAP-Deleted Tumors

[TFMG]

$AGIO Bullish after-hours 15% move on positive 8-K filing

Shares have made a very positive move afterhours on good volume after the release of its 8-K Inc announcing that the global phase 3 ClarIDHy trial of TIBSOVO® (ivosidenib) in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 mutation met its primary endpoint. Tomorrow will be a very positive day so be ready, it could move very fast.

[Hyah]

AGIOS UP BIG AFTER HOURS

[debunker1]

Agios just another pump and dump??

Be careful investors, do your research, take a closer look. Agios is a company involved in developing biologic drugs.....the CSO of Agios is a chemist..... the person holding such a position is supposed to be a biologist, someone with a background in biology, not small molecule drugs.


The truth is the CSO has no experience in his background to make him suitable for such a position.....

[grow fast]

VistaTrades issed a BUY signal for AGIO on 4.17.17

[stockdawg44]

AGIO $64.00, sweetness....

[stockdawg44]

AGIO $55.60 pre market...weeeeeeeeeeeeeeeeeeeee

[stockdawg44]

AGIO $54 and more to come.....yea baby.....

[stockdawg44]

AGIO $52.30

[stockdawg44]

AGIO $50 coming soon......monster in the making here!

[stockdawg44]

AGIO, nice bottom bounce play here.... +$2.55

[Buzz301]

Could easily hit $50 by tomorrow.

[stockdawg44]

R2G, great support $46+ AGIO

[stockdawg44]

low vol, let's hit $50+ today.....AGIO

[ClearlyStocks]

AGIO $48.90 p/m

[stockdawg44]

AGIO, back to $47.00 she's got legs.......glad I held the (3 hour dip) lol

[ClearlyStocks]

AGIO $47.75 getting there

[stockdawg44]

grabbed some @ $46.50 1K, c'mon $50 AGIO

[ClearlyStocks]

AGIO $47.39

[ClearlyStocks]

AGIO $47.18

[ClearlyStocks]

AGIO $46.93

[ClearlyStocks]

AGIO $46 !!!!!

[ClearlyStocks]

AGIO $42.98

[crudeoil24]

Agios Pharmaceuticals, Inc. (the “Company”) today announced that its collaboration partner Celgene Corporation (“Celgene”) expects to submit a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for enasidenib (AG-221), a first-in-class, oral, selective, potent inhibitor of mutant isocitrate dehydrogenase-2 (“IDH2”), in relapsed and/or refractory acute myeloid leukemia (“AML”). The NDA will be based on data from the ongoing phase 1/2 study of AG-221 in patients with advanced hematologic malignancies with an IDH2 mutation. The NDA submission is expected to occur by year-end 2016. Celgene will be discussing the planned enasidenib NDA submission at the Citi 11th Annual Biotech Conference in Boston in a webcast event on Wednesday, September 7, 2016 at 12:00 pm ET.

[ClearlyStocks]

AGIO $41.70 ca$h money

[ClearlyStocks]

AGIO $40.60 wow

[ClearlyStocks]

AGIO $39.97 going. $40+

[ClearlyStocks]

AGIO $38.40

[NathanH]

In at 36.6